COVID-19 Antibodies: America Announces Clinical Trial Of New Antibody Treatment, LY-CoV555 For COVID-19
: The United States has begun late stage clinical trials into a drug formulated to fight COVID-19, officials said Tuesday.
The drug is an antibody against the new coronavirus called LY-CoV555, which was identified in the blood sample of a recovered patient by Canada's Abcellera Biologics.
The identified antibody was then developed synthetically for mass production by US-based Lilly Research Laboratories in partnership with Abcellera.
The soon to be Phase 3 trial will initially enroll some 300 volunteers around the world who have been hospitalized with mild to moderate COVID-19 with fewer than 13 days of symptoms. (it should be noted that for a Phase 3 trial the number of proposed participants are considered small.)
Each participant will be assigned either the medicine, which will be injected intravenously, or a placebo.
Certain patients will also receive standard care for COVID-19, including the antiviral remdesivir.
Please Help To Donate To Sustain This Site And Other Research We Are Propelling. Thank You. https://www.thailandmedical.news/p/sponsorship
The approved Phase 3 trial is being led by Dr Jens Lundgren, of the University of Copenhagen and Rigshospitalet, and could expand to up to 1,000 people, including the more severely ill, if LY-CoV555 appears safe and effective after the fifth day.
The phase 3 trial's main goal is the patients' sustained recovery for 14 days after release from the hospital.
Also, the new drug is also being tested on people with mild to moderate symptoms of COVID-19 who have not been hospitalized, as part of a parallel middle-stage trial also announced Tuesday.
Dr Anthony Fauci, director of the National Institutes of Allergies and Infectious Diseases said, "Studying the impact of this investigational therapeutic on multiple patient populations at the same time is critical to determining whether it can help COVID-19 patients with differing levels of disease severity."
Typically, antibodies are infection-fighting proteins made by the immune system that can bind to the surface of viruses and prevent them from invading cells. Whereas vaccines work by teaching the body to make its own antibodies, while scientists are also testing ready-made antibodies from the blood of recovered patients, called convalescent plasma. However it is not possible to make convalescent plasma a mass treatment.
Most researchers can would comb through the antibodies produced by recovered patients and select the most effective out of thousands, and then manufacture it at scale.
For the latest on COVID-19 Antibodies
, keep on logging to Thailand Medical News.
)">Please Help To Donate To Sustain This Site And Other Research We Are Propelling. Thank You. https://www.thailandmedical.news/p/sponsorship